Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Parkinsons Disease (PD): early-phase trial registry
13 of 20 indexed Parkinsons Disease (PD) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 13 currently recruiting · #848 of 28,707 conditions by registered trial count
Parkinsons Disease (PD): 20 US clinical trials tracked, 13 recruiting.
Parkinsons Disease (PD) is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is AbbVie, running 5 of these trials.
Enrollment posture brief
Registry condition parkinsons-disease-pd
OPEN 13 | RECR 65% | LATE 5 | EARLY 8 | RANK #848 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Focal Segmental Glomerulosclerosis (65% recruiting · 20 trials)
Parkinsons Disease (PD) lists 13 open slots (65% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Parkinsons Disease (PD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Parkinsons Disease (PD) is recruiting above its size-band peers.
13 of 20 indexed trials (65%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Parkinsons Disease (PD) research.
AbbVie accounts for 5 of 20 trials (25%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Parkinsons Disease (PD) trials plan to enrol fewer than 100 people.
Median target enrolment is 77 among the 20 trials that report a genuine target (sentinel values excluded). 13 of those (65%) plan for fewer than 100 participants.
-
Parkinsons Disease (PD) research is mostly interventional.
18 interventional and 2 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
A Study of Buntanetap in Participants With PD
Annovis Bio
NCT07284784
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
AbbVie
NCT06107426
Neuroimaging of Parkinson's
Washington University School of Medicine
NCT07024875
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
BlueRock Therapeutics
NCT06944522
Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations
University of Colorado, Denver
NCT07424365
Investigating Subcortical Contributions to Speech Sequencing in Deep Brain Stimulator Recipients
Boston University Charles River Campus
NCT07455760
Effects of Vagal Nerve Stimulation on Leg Muscle Activity and Posture in Parkinson's Disease
University of Minnesota
NCT07226284
Transcranial Direct Current Stimulation for Motor Function and Fatigue in PD
Sanford Health
NCT06883266
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
TrueBinding
NCT06773962
A Study of NE3107 in Early Parkinson's
BioVie
NCT06757010
Electrophysiology-based DBS Programming for PD
University of Florida
NCT07348705
Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease
Invicro
NCT07348250
Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
Pravat Mandal
NCT07064005
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
AbbVie
NCT04379050
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
AbbVie
NCT04750226
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Adamas Pharmaceuticals
NCT02202551
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
Adamas Pharmaceuticals
NCT02274766
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
AbbVie
NCT03033498
A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
AbbVie
NCT03374917
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
Molecular NeuroImaging
NCT02103894
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 3 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Parkinsons Disease (PD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Parkinsons Disease (PD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Parkinsons Disease (PD) page
20 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Parkinsons Disease (PD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AbbVie sponsors the most Parkinsons Disease (PD) trials on record, review their full trial history before evaluating a specific study. See AbbVie's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Parkinsons Disease (PD) condition card totals 20 registered trials; most-linked intervention ABBV-951; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.